Erkang's net profit dropped 56.65% year on year, mainly due to these three points

On February 27, Erkang Pharmaceutical (300267) released the performance express report From January to December 2018, the company achieved an operating revenue of 2.380 billion yuan, a year-on-year decrease of 15.86%, and the average operating revenue growth rate of the chemical pharmaceutical industry was 23.73%; the net profit attributable to shareholders of listed companies was 227 million yuan, a year-on-year decrease of 56.65%, and the average net profit growth rate of the chemical pharmaceutical industry was 0.03% During the reporting period, the company realized operating revenue of 2379515772.30 yuan, a decrease of 15.86% over the previous year; operating profit of 360494255.60 yuan, a decrease of 38.82% over the previous year; total profit of 282562015.12 yuan, a decrease of 52.16% over the previous year; net profit attributable to shareholders of the listed company of 226507 yuan, 167.70 yuan, down 56.65% over the previous year; basic earnings per share was 0.1098 yuan, down 56.65% over the previous year The main reasons for the year-on-year decline of the above indicators are as follows: (1) influenced by the pharmaceutical industry environment and industry policies, the sales volume of modified starch, starch capsule and other products produced by the company decreased compared with the same period of last year, and its sales revenue decreased by 79.77% compared with the same period of last year (2) During the reporting period, in order to promote superior products and maintain end customers, the company strengthened market promotion and sales network construction In 2018, the sales expense increased by 50.12% compared with the same period last year (3) During the reporting period, the amount of non recurring profit and loss decreased by 101.3947 million yuan compared with the same period of last year, mainly due to the increase of non operating expenses caused by the estimated liabilities in the case of Securities Misrepresentation liability dispute and the payment of fines by subsidiaries.